Latest news with #CB1
Yahoo
28-05-2025
- Business
- Yahoo
CBD Life Sciences Inc. (CBDL) Announces New Powerful 500MG THC Delta-8 Gummy
With Delta-8 product revenue continuing to climb, CBDL introduces a lab-tested gummy formulation to meet surging demand in a market projected to exceed $2.1 billion by 2026. SCOTTSDALE, AZ / / May 28, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a rising force in the cannabinoid wellness industry, is proud to announce the latest addition to its growing Delta-8 product lineup: a premium, lab-tested Delta-8 THC gummy, developed in-house to ensure consistency, potency, and quality at every step. Building on the success of its existing Delta-8 offerings, this new gummy marks another strategic milestone in CBDL's mission to dominate the cannabinoid edibles market. Crafted in a controlled lab environment, this new edible is designed for consumers who prioritize quality, effectiveness, and a clean, smooth Delta-8 experience. "We've already seen strong performance across our Delta-8 line, and this gummy is a direct response to customer demand for more convenient, enjoyable, and effective ways to experience its benefits," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "As always, we're delivering a product that's backed by science, produced in-house, and driven by results." Delta-8 THC: Expanding the Future of Functional WellnessUnlike traditional Delta-9 THC, Delta-8 offers a milder, clearer psychoactive experience - making it a preferred option for wellness seekers, first-time users, and individuals looking for a balanced high without anxiety. CBDL's newly formulated Delta-8 gummies are not just about effect - they're designed to deliver real therapeutic value. Below is a breakdown of the core wellness benefits supported by research and consumer feedback: Pain Relief • Engages the endocannabinoid system to help regulate pain• May reduce inflammation that contributes to chronic discomfort Anxiety & Stress Support • Natural calming effects to help manage daily stress and reduce anxiety• Promotes overall mood balance without sedation Nausea Control • Anti-emetic potential makes it a powerful option for those undergoing chemotherapy or other nausea-inducing treatments Appetite Stimulation • Ideal for individuals with appetite loss or dietary imbalances related to health conditions Neuroprotective Potential • Early research suggests Delta-8 THC may contribute to long-term brain health through its interaction with CB1 receptors Made In-House. Backed by Lab many mass-produced gummies on the market, CBDL maintains full control over every phase - from formulation to packaging - in its in-house manufacturing facility. Each batch is independently lab-tested to guarantee purity, potency, and compliance, giving consumers complete confidence in what they're consuming. Strategic Growth for Shareholders & StakeholdersDelta-8 THC products have already proven to be one of CBDL's strongest performing categories, and this launch further solidifies the company's aggressive expansion in the high-growth cannabinoid edible space. The market for Delta-8 continues to gain national momentum, with sales projections showing compound annual growth that far outpaces many traditional supplement sectors. "This gummy is just one part of a much larger product ecosystem we're building - focused on in-demand cannabinoids, real health outcomes, and market scalability," said Nelson. Product Details • Product: Delta-8 THC Gummy• Type: Vegan, In-House Formulated, Lab-Tested• MG per Gummy: 500MG• Availability: Launching via Flavors: Blue Razz & Strawberry About CBD Life Sciences Inc. (CBDL)CBD Life Sciences Inc. is a vertically integrated health and wellness company focused on cannabinoid innovation. With a robust pipeline of CBD, Delta-8, and other hemp-derived formulations, CBDL operates across direct-to-consumer, retail, and wholesale channels - including recent distribution on Walmart Marketplace and additional platforms coming soon. Follow our social media for the latest updates!X: Contact: cbdvaultaz@ Stay Connected & Be the First to Try Our New Functional Mushroom Products! Mushroom Madness Instagram: Mushroom Madness Website: Forward-Looking StatementsExcept for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Safe Harbor StatementThis release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements. Contact InformationLisa NelsonCEOcbdvaultaz@ SOURCE: CBD Life Sciences Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
27-05-2025
- Business
- Business Wire
Results of Aelis Farma Combined General Meeting of May 27, 2025
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB 1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders. Aelis Farma held its combined general meeting of shareholders on May 27, 2025, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors. With a quorum of 74.42 %, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of directors related to financial transactions. The General Assembly also renewed the term of office of all the directors. Mr. Anders Gersel Pedersen was reappointed as Chairman of the Board of Directors. Detailed results of the vote on all resolutions, as well as the recording of the general meeting, will be available on the Company's website within the legal time frame. About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB 1 receptor of the endocannabinoid system (CB 1 -SSi). CB 1 -SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB 1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB 1 -SSi appear to selectively inhibit the disease-related activity of the CB 1 receptor without disrupting its normal physiological activity. CB 1 -SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases. Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB 1 -SSi in humans. The Company also has a portfolio of new innovative CB 1 -SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB 1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB 1 -SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB 1 receptor and guaranteeing that the different compounds are not substitutable one with the others. Aelis Farma draws on the talents of more than 25 highly qualified employees. For more information, visit and follow us on LinkedIn and Twitter. ISIN: FR0014007ZB4 Ticker: AELIS B Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D-25.0314. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.
Yahoo
13-05-2025
- Health
- Yahoo
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small molecule-based CB1 inhibitors, which both exhibited increasing dose-dependent brain penetration • This model predicts nimacimab's potentially superior therapeutic index, which is dependent on minimal brain exposure while maintaining sufficient peripheral inhibition SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, presented a clinical pharmacokinetic ('PK') and pharmacodynamic ('PD') model that underscores the fundamental relationship between biodistribution and efficacy of CB1 inhibitors at the annual European Congress on Obesity meeting. This model demonstrated that achieving strong peripheral CB1 inhibition is sufficient to achieve efficacy, including weight loss. In contrast, blocking CB1 in the brain (central inhibition), which is associated with neuropsychiatric side effects, is not enough on its own to achieve weight loss. Published clinical PK and potency data coupled with Phase 2 ('P2') and Phase 3 efficacy data from Novo Nordisk's monlunabant and Sanofi's rimonabant, respectively, as well as Phase 1 data from nimacimab were used to develop a model to determine whether peripheral CB1 inhibition alone is sufficient for weight loss, or if central inhibition is also required for optimal efficacy. The results showed that central inhibition of CB1 alone was not sufficient for weight loss with P2 data for monlunabant, and demonstrated that increasing drug levels in the brain did not improve efficacy. Relatedly, monlunabant's Ph2 dose range established that all doses achieved significant peripheral inhibition, resulting in significant but similar weight loss. The model also showed that a 5 mg dose of rimonabant that had significant levels in the brain but not peripherally was not effective, leading to only minimal weight loss. 'This model meaningfully advances our understanding of how CB1 inhibitors work, demonstrating that peripheral and not central target engagement is foundational to achieving efficacy including weight loss. Moreover, it clarifies how the therapeutic index of CB1 inhibitors is tied to the relationship between receptor inhibition in the brain, or centrally, versus peripherally--and the widest therapeutic index is associated with the greatest peripheral restriction,' said Punit Dhillon, CEO. 'Our clinical model, together with Skye's recent mouse diet-induced obesity studies, highlights that nimacimab can potentially achieve significant weight loss with a molecule uniquely restricted to tissues outside the brain. We believe nimacimab's highly favorable therapeutic index sets our antibody-based drug apart from small-molecule CB1 inhibitors.' Beyond the relationship with weight loss, using reported safety data from the same clinical trials allowed the model to provide further insight into the therapeutic index of different CB1 inhibitors. Unlike weight loss, neuropsychiatric adverse events such as anxiety and mood changes became present and escalated as CB1 inhibition in the brain increased. While nimacimab has been shown to be virtually undetectable in the brain, penetration into the brain is a challenge small molecule CB1 inhibitors such as rimonabant and monulunabant continue to face. Dr. Chris Twitty, Chief Scientific Officer added, 'While the sufficiency of peripheral CB1 inhibition, as it relates to metabolic gains including weight loss, has been demonstrated preclinically in tissue-specific knock-out systems, our modeling provides a clinical lens that demonstrates parallel findings. Our data show that nimacimab's Phase 2 dose achieves peripheral CB1 engagement at more than seven times the inhibition threshold, while remaining over 600 times below this threshold in the brain. We remain confident in our belief that the Phase 2 dose of nimacimab will be safe and effective, with potent inhibition and a favorable PK profile in the periphery with very little presence in the brain.' The poster can be accessed on Skye's Spotlight page. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial ( NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: Connect with us on X and LinkedIn. CONTACTS Investor Relationsir@ 410-0266 LifeSci Advisors, Mike Moyermmoyer@ 308-4306 Media InquiriesLifeSci Communications, Michael Fitzhughmfitzhugh@ 234-3889 FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including 'anticipated,' 'plans,' 'goal,' 'focus,' 'aims,' 'intends,' 'believes,' 'can,' 'could,' 'challenge,' 'predictable,' 'will,' 'would,' 'may' or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to: (i) statements regarding the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, (ii) statements relating to any expectations regarding the efficacy and therapeutic potential of nimacimab as a monotherapy or in combination with a GLP-1 targeted drug, including expectations based on clinical models of rimonabant and monlunabant and nimacimab , (iii) statements regarding nimacimab's potential to achieve significant weight loss, and (iv) statements regarding superior potency of nimacimab to other small molecule CB1 inhibitors based on nimacimab's mechanism of action. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
Yahoo
07-05-2025
- Business
- Yahoo
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
Skye Bioscience, Inc. SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay and transcript will be available at the same website. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial ( NCT06577090 ) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: . Connect with us on X and LinkedIn . CONTACTS Investor Relations ir@ (858) 410-0266 LifeSci Advisors, Mike Moyer mmoyer@ (617) 308-4306 Media Inquiries LifeSci Communications, Michael Fitzhugh mfitzhugh@ (628) 234-3889
Yahoo
11-03-2025
- Health
- Yahoo
Brain Receptors For Cannabis Could Be Why Some People Are More Resilient
A receptor that cannabis latches onto in the brain could be a promising target for future mental health treatments. Experiencing chronic stress is known to leave people vulnerable to depression or anxiety, and a new study on mice suggests cannabinoid receptors might be the reason some of us show more resilience in the face of overwhelming pressure. Led by researchers at the University of Laval in Canada, the study found that mice with increased levels of cannabinoid receptor 1 (CB1) on certain brain cells show significantly fewer behaviors associated with anxiety or depression, even when they are subject to chronic social stress. The results have neuroscientists hypothesizing that CB1, the most common cannabinoid receptor in the brain, may have a protective role to play against two of the most common mental health disorders. CB1 can be activated by natural neurotransmitters in the body or by cannabis, and among many other crucial bodily functions, it plays a fundamental role in stress responses. The findings don't necessarily imply that cannabis as a drug can protect the brain from chronic stress, but researchers say it does suggest the possibility of trying similar yet more targeted molecules in future drug trials. "The challenge, however, is to limit their effects to astrocytes, because strong and prolonged activation of the same receptors in neurons can have side effects, notably on alertness, anxiety and appetite," explains neuroscientist Caroline Ménard, who heads the lab at Laval. The majority of CB1 receptors in the brain act on neurons, but some of these triggers are also found on non-neuronal cells called astrocytes. Astrocytes are the most common cell in the central nervous system, and recently, they have emerged as key regulators of cognitive function. The 'feet' of these star-shaped cells press up against blood vessels in the brain, creating a protective barrier through which only certain molecules can flow. According to the new experiments on mice, CB1 receptors play a crucial role in maintaining the integrity of this blood-brain barrier. Previous studies have found that chronic stress in mice damages the blood-brain barrier, increasing inflammation in the brain and leading to the animals acting in depressed ways. If the blood-brain barrier is kept intact, however, the depressive-like behaviors, including social avoidance, anhedonia, and anxiety, are reduced. "We noticed that mice resilient to stress had more CB1 receptors in the barrier than mice with depressive-like behavior or mice not exposed to stress," explains Ménard. "That gave us the idea to investigate the role of astrocytic CB1 receptors in the response to chronic stress." Ménard and her colleagues induced some mice brains to over-express CB1 receptors on certain astrocytes. By doing so, the researchers showed they could reduce inflammation in the brain, maintain the integrity of the blood-brain barrier, and hold off symptoms of anxiety and depression, even when they were socially harassed by aggressive mice for days on end. Physical activity had a remarkably similar effect to the over-expression of CB1 receptors. Mice that were genetically altered to be missing the genes for this receptor, however, were highly sensitive to stress. The researchers only altered CB1 expression in two brain regions where the blood-brain barrier seems most vulnerable to stress: the nucleus accumbens – associated with reward and mood regulation – and the prefrontal cortex – associated with social behaviors, decision-making, and executive function. Upon examining postmortem human brains, Ménard says she and her team, including lead author Katarzyna Dudek, found the level of CB1 receptors on astrocytes in these parts of the brain was "lower in people with major depression at the time of death than in people without depression or those treated with antidepressants." This validates the animal models, but more research is needed for a broader picture. The authors only measured one marker of inflammation in the brain, which does not fully reflect the complexity of the endocannabinoid system. "Until we find a molecule that acts specifically on CB1 receptors in astrocytes, we can mitigate the negative repercussions of stress by taking advantage of the protective effect of physical activity," says Ménard. The study was published in Nature Neuroscience. A Hidden Awakening in The Brain May Explain Why Females Age Slower Men Have Higher Risk of Parkinson's, And We May Finally Know Why An Ancient Disease Has Reappeared in The US. This Could Be Why.
